Odronextamab

Odronextamab, sold under the brand name Ordspono, is a CD20 x CD3 bispecific monoclonal antibody that is used for the treatment of follicular lymphoma or diffuse large B-cell lymphoma.^[1][2] It was developed by Regeneron Pharmaceuticals.^[1]

Odronextamab

Monoclonal antibody
Type	Bi-specific T-cell engager
Source	Humanized
Target	CD20, CD3
Clinical data
Trade names	Ordspono
Other names	REGN1979; REGN-1979
Drug class	Antineoplastic
ATC code	L01FX34 (WHO)
Legal status
Legal status	EU: Rx-only[1][2]
Identifiers
CAS Number	1801338-64-6
DrugBank	DB16684
UNII	8R5CM46UIO
KEGG	D11534
Chemical and physical data
Formula	C6458H9950N1728O2020S46
Molar mass	145593.47 g·mol−1

The most common side effects include cytokine release syndrome, infections, neutropenia, pyrexia (fever), anemia, thrombocytopenia, and diarrhea.^[1]

Odronextamab was approved for medical use in the European Union in August 2024.^[1][2]

Medical uses

Odronextamab is indicated for the treatment of adults with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy;^[1] and for the treatment of adults with relapsed or refractory diffuse large B‑cell lymphoma after two or more lines of systemic therapy.^[1]

Side Effects

The most common side effects include cytokine release syndrome, infections, neutropenia, pyrexia, anemia, thrombocytopenia, and diarrhea.^[1]

Society and culture

Legal status

In June 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a conditional marketing authorization for the medicinal product Ordspono, intended for the treatment of follicular lymphoma and diffuse large B-cell lymphoma.^[1][3] The applicant for this medicinal product is Regeneron Ireland Designated Activity Company.^[1] Odronextamab was approved for medical use in the European Union in August 2024.^[1][2][4]

Names

Odronextamab is the international nonproprietary name.^[5]